Hospital
O'connor Hospital
O'connor Hospital was paid $2.84M by Medicaid between Sep 2019 and Nov 2024, across 66 billing codes. Its largest line is 99283, emergency room visit (moderate) — 23% of everything it billed.
33Billing provider infoO'CONNOR HOSPITAL
DELHI, NY 13753
DELHI, NY 13753
33aNPI1801975156assigned 11/06/2006
33bProvider typeMedicare Defined Swing Bed Hospital Unit
28Total paid$2.84M
24GClaims33,910
24DCodes billed66
24AFirst – last monthSep 2019 – Nov 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 1,048 | $53K | |
| 2020 | 3,216 | $193K | |
| 2021 | 6,180 | $374K | |
| 2022 | 8,612 | $1.18M | |
| 2023 | 8,334 | $645K | |
| 2024incomplete | 6,520 | $397K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 23% | 3,045 | 2,897 | $652K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 8.8% | 1,383 | 1,300 | $249K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.8% | 1,267 | 1,221 | $223K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 6.9% | 2,359 | 778 | $198K |
| 80053 | Comprehensive metabolic panel | 6.9% | 2,454 | 2,184 | $195K |
| 36415 | Collection of venous blood by venipuncture | 6.8% | 2,300 | 2,075 | $193K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.6% | 1,261 | 1,177 | $158K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 5.3% | 817 | 797 | $151K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 5.0% | 636 | 616 | $141K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.8% | 360 | 351 | $109K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 2.2% | 425 | 425 | $64K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.0% | 66 | 65 | $58K |
54 more codes
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.0% | 1,222 | $56K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.9% | 158 | $54K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.8% | 3,415 | $52K |
| 77063 | Screening digital breast tomosynthesis, bilateral | 1.8% | 368 | $51K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.4% | 1,223 | $40K |
| 81025 | 1.2% | 302 | $33K | |
| 80061 | Lipid panel | <1% | 396 | $21K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 155 | $20K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 327 | $17K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 215 | $12K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 52 | $11K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 185 | $11K |
| 97161 | <1% | 90 | $10K | |
| 83735 | <1% | 1,294 | $8K | |
| 80051 | <1% | 272 | $7K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,052 | $7K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 299 | $5K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 57 | $5K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 12 | $4K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 26 | $3K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 126 | $3K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 238 | $3K |
| 82565 | <1% | 458 | $3K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 521 | $2K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 15 | $2K |
| 85027 | <1% | 96 | $2K | |
| 81001 | <1% | 951 | $2K | |
| 87634 | <1% | 37 | $2K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 32 | $1K |
| 83690 | <1% | 964 | $881.60 | |
| 0012A | <1% | 28 | $764.10 | |
| 0011A | <1% | 28 | $760.10 | |
| 84520 | <1% | 311 | $758.29 | |
| 84450 | <1% | 158 | $688.37 | |
| 73630 | <1% | 12 | $643.50 | |
| 81003 | <1% | 293 | $505.31 | |
| 82947 | <1% | 307 | $483.43 | |
| 82607 | <1% | 13 | $376.70 | |
| 84484 | <1% | 203 | $308.66 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 26 | $207.26 |
| 71045 | Radiologic examination, chest; single view | <1% | 17 | $163.98 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 25 | $117.77 |
| 85652 | <1% | 12 | $96.40 | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 533 | $92.14 |
| 82550 | <1% | 14 | $70.08 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 121 | $63.14 |
| J3490 | Unclassified drugs | <1% | 24 | $51.83 |
| 82040 | <1% | 101 | $22.54 | |
| 82247 | <1% | 102 | $16.94 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 405 | $2.75 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 169 | $0.16 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 0% | 12 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 51 | $0.00 |
| 80320 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialAYERS, DANIEL (CEO)
| Provider | Location | Paid |
|---|---|---|
| Apex Medical Transport, INC. | New Hartford, NY | $391K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.